company background image
BNTX N logo

BioNTech BMV:BNTX N Stock Report

Last Price

Mex$1.52k

Market Cap

Mex$361.1b

7D

3.2%

1Y

-35.7%

Updated

27 Mar, 2024

Data

Company Financials +

BNTX N Stock Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

BNTX N fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

BioNTech SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioNTech
Historical stock prices
Current Share PriceUS$1,520.00
52 Week HighUS$2,300.00
52 Week LowUS$1,472.60
Beta0.23
1 Month Change-4.88%
3 Month Change-14.56%
1 Year Change-35.73%
3 Year Change-31.99%
5 Year Changen/a
Change since IPO-21.57%

Recent News & Updates

Recent updates

Shareholder Returns

BNTX NMX BiotechsMX Market
7D3.2%0%0%
1Y-35.7%0%0%

Return vs Industry: BNTX N underperformed the MX Biotechs industry which returned 2.8% over the past year.

Return vs Market: BNTX N underperformed the MX Market which returned 4.2% over the past year.

Price Volatility

Is BNTX N's price volatile compared to industry and market?
BNTX N volatility
BNTX N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: BNTX N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BNTX N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20086,133Ugur Sahinhttps://www.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.

BioNTech SE Fundamentals Summary

How do BioNTech's earnings and revenue compare to its market cap?
BNTX N fundamental statistics
Market capMex$361.09b
Earnings (TTM)Mex$16.68b
Revenue (TTM)Mex$68.48b

21.9x

P/E Ratio

5.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNTX N income statement (TTM)
Revenue€3.82b
Cost of Revenue€599.80m
Gross Profit€3.22b
Other Expenses€2.29b
Earnings€930.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 06, 2024

Earnings per share (EPS)3.91
Gross Margin84.29%
Net Profit Margin24.36%
Debt/Equity Ratio0.01%

How did BNTX N perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.